JAZZ Jazz Pharmaceuticals PLC

$176.93

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

Website: https://www.jazzpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1232524
Address
FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IE
Valuation
Market Cap
$6.24B
P/E Ratio
11.88
PEG Ratio
0.32
Price to Book
1.52
Performance
EPS
$8.65
Dividend Yield
—
Profit Margin
13.80%
ROE
14.30%
Technicals
50D MA
$128.48
200D MA
$118.45
52W High
$148.06
52W Low
$95.49
Fundamentals
Shares Outstanding
61M
Target Price
$192.22
Beta
0.42

JAZZ EPS Estimates vs Actual

● Estimated
● Actual

JAZZ News & Sentiment

Nov 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Nov 18, 2025 • Benzinga SOMEWHAT-BULLISH
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 - Avant Technologies ( OTC:AVAI ) , Annovis Bio ( NYSE:ANVS )
NEW YORK, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focused health.
Nov 18, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Nov 18, 2025 • Benzinga SOMEWHAT-BULLISH
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Nov 18, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative ...
Nov 18, 2025 • Benzinga SOMEWHAT-BULLISH
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets - Zymeworks ( NASDAQ:ZYME )
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders
Sentiment Snapshot

Average Sentiment Score:

0.131
50 articles with scored sentiment

Overall Sentiment:

Neutral

JAZZ Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
-0.63 Surprise
  • Reported EPS: $-8.25
  • Estimate: $-7.62
  • Whisper: —
  • Surprise %: -8.3%
May 06, 2025
Mar 31, 2025 (Pre market)
-6.33 Surprise
  • Reported EPS: $-1.52
  • Estimate: $4.81
  • Whisper: —
  • Surprise %: -131.6%
Feb 25, 2025
Dec 31, 2024 (Post market)
0.79 Surprise
  • Reported EPS: $6.60
  • Estimate: $5.81
  • Whisper: —
  • Surprise %: 13.6%
Nov 06, 2024
Sep 30, 2024 (Post market)
1.11 Surprise
  • Reported EPS: $6.61
  • Estimate: $5.50
  • Whisper: —
  • Surprise %: 20.2%
Jul 31, 2024
Jun 30, 2024 (Post market)
0.53 Surprise
  • Reported EPS: $5.30
  • Estimate: $4.77
  • Whisper: —
  • Surprise %: 11.1%
May 01, 2024
Mar 31, 2024 (Post market)
-1.5 Surprise
  • Reported EPS: $2.68
  • Estimate: $4.18
  • Whisper: —
  • Surprise %: -35.9%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.16 Surprise
  • Reported EPS: $5.02
  • Estimate: $5.18
  • Whisper: —
  • Surprise %: -3.1%
Nov 08, 2023
Sep 30, 2023 (Post market)
-0.09 Surprise
  • Reported EPS: $4.84
  • Estimate: $4.93
  • Whisper: —
  • Surprise %: -1.8%
Aug 09, 2023
Jun 30, 2023 (Post market)
0.08 Surprise
  • Reported EPS: $4.51
  • Estimate: $4.43
  • Whisper: —
  • Surprise %: 1.8%

Financials